CLBS - Caladrius rallies on approval of merger name change to Lisata Therapeutics

• Caladrius Biosciences ( NASDAQ: CLBS ) announced that its stockholders approved all of the merger-related proposals by Caladrius and Cend Therapeutics, and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius’ common stock to Cend’s stockholders.
• Subsequent to the stockholders’ approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius’ common stock at a ratio of one new share for every fifteen shares outstanding.
• The reverse stock split will become effective today, Sept. 14, 2022, at 5:00pm EST.
• The consolidated common shares for the combined company, which will be renamed Lisata Therapeutics, are expected to commence trading on Nasdaq under the symbol “LSTA” on Sept. 15, 2022, at 9:30am EST.
• CLBS +39.28% premarket to $0.71.

For further details see: